If you haven't listened you should, haven't heard this level of confidence (genuine, real-deal-confidence) since I've been in this stock since 2009.
With 70% chance for prophylactic success with 7353 and now the acute treatment positive results, competing big pharma in the HAE space should be at the table.
A patient population able to have an all oral solution for prophylactic and acute treatment conveniently available at home or for travel is a high quality product.
BCRX is positioned for the long haul but that can be upended with a B/O...OCT.??? $15-$20.
http://wsw.com/webcast/baird52/register.aspx?conf=baird52&page=bcrx&url=http://wsw.com/webcast/baird52/bcrx/index.aspx